[ad_1]
Behind the catastrophically bad image of the Russian vaccine is a system of state institutions designed to manage it, according to a Russian expert who may explain why Sputnik could be among the first in line for vaccinations against the coronavirus.
Why the Russian coronavirus vaccine went cold while Western formulations developed in parallel progressed with good public relations towards its use. Thus, we could blame the Russian phobia of the West, as well as Russian President Vladimir Putin, who forced the vaccine to be licensed before testing was complete, but based on previous Russian drug developments, a different explanation seems. logic. The repetition of the two-handed management is striking. One thing is for sure: It’s not the quality of the vaccine that’s wrong, says Leonid Bershidsky, a Russian-born publicist for Bloomberg in Germany.
The main developer of the Sputnik V vaccine was Denis Logunov (in the center of our image), a well-known and well-known microbiologist who, after age 42, could not be classified as a Soviet dinosaur species. The team he led in 2016 at the Gamaleja Research Center, whose senior staff developed an Ebola vaccine that proved effective in tests, followed by a vaccine against a virus called MERS, but to no avail it outperformed many of its foreign competitors .
Kopi paste
With this development experience, Logunov and his colleagues may have been at the forefront of developing coronavirus vaccines. In practice, they had to repeat their previous genetic engineering method, as the researcher told the Latvian Internet portal Meduza in one of his rare interviews, using the well-known copy-paste method of computer science. Of course, experts in the West knew this too, so they were aware that the development of Russian vaccines was very serious.
The main problem, according to a Bloomberg publicist, is that Gamaleja is a typical Russian state institution that is incapable of culturally managing what its professionals bring to the table. At the same time, Logunov and similar talents in Russia can do nothing but work in such institutions, his hand, as he said in the interview, is personally bound by the fact that his experience is limited to a very narrow field of science. .
Fool busting
The marketing disaster began when the Russian pharmaceutical authority announced the authorization of Sputnik for the first time in the world in August, while third-round tests had not yet been completed, so it was not known what side effects the drug could have. . This is particularly absurd in light of the fact that Western countries have been constantly experimenting with various drugs to cure coronavirus disease, on which it was also not possible to know exactly what effect they would have on patients. However, they didn’t make the mistake of hitting this on a big drum.
While the Russian vaccine fell into the crosshairs of critics after August, manufacturers of other similar formulations quietly agreed with governments on the quantities to be delivered, meaning they were sold prior to manufacture, gaining market access for the new vaccine. The bad start also made it difficult for Gamaleja to tie up production capacities in other countries of the world to produce Sputnik.
What a western license for us!
The State Development Fund (RDIF), which funded the development of the vaccine, is a paper-based institution, but that was not the last straw, the writer of the Bloomberg article said. Rather than trying to get a market for Sputnik, he targeted the most anti-Western countries of the developed countries, such as Iran or Nicaragua. The fund’s director, Kirill Dmitriev, said in early February that emerging in western markets was not one of RDIF’s priorities because these countries did not want to work with Russia for political reasons.
This raises the question whether the organization did not intend to demonstrate: while the West wants to push Russia to the periphery, the rest of the world is willing to cooperate with it. In other words, it is not the Russian system that is to blame, but the Western partners. The bottom line, according to a Bloomberg publicist, is that the Russian government has used taxpayers’ money to support an effective and competitive product with great skulls behind it, but slow and politicized marketing and distribution make it impossible for the Sputnik V vaccine. become a world-renowned hit.
[ad_2]
